STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
At the ASCO annual meeting, Bristol-Myers Squibb presented positive data regarding its treatment for multiple myeloma. Meanwhile, Pfizer showcased promising results for its lung cancer therapy. These developments highlight ongoing advancements in cancer treatment and drug development.
- ▪Bristol-Myers Squibb reported positive data for its multiple myeloma treatment at ASCO.
- ▪Pfizer presented encouraging results for its lung cancer therapy during the conference.
- ▪The ASCO annual meeting serves as a significant platform for cancer research advancements.
Opening excerpt (first ~120 words) tap to expand
STAT PlusHealth At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer Manage alerts for this article Email this article Share this article Chicago, where thousands in the cancer world gather each year.Adam Feuerstein/STAT By Adam Feuerstein, Matthew Herper, and Angus ChenMay 29, 2026 Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT News.
Discussion
0 commentsMore from STAT News
